In this episode, James and Sapna debate how to pronounce the newest FDA approved treatment for melanoma: T-U-D-R-I-Q-E-V

They discuss the FDA Cell and Gene Therapy Advisory Committee's review of the single-arm IGNYTE data and key issues around if this represents a local or systemic therapy, the maths around calculating response rate, and importantly how to identify optimal tumor characteristics for this treatment - what Sapna calls "Larkin-izing" the data.

It's a long episode with a short fact check and lots of shoutouts to Kevin Harrington for his work in this space.

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör Melanoma Matters Pod. Innehållet i podden är skapat av Melanoma Matters Pod och inte av, eller tillsammans med, Poddtoppen.